HEALTH AND OCCUPATIONAL EXPOSURE TO ANTI-CANCER DRUGS

本研究的目的是确定是否处理 为接受治疗的病人提供药物或护理 这些药物对工作人员的健康构成风险， 评估工作实践与各种 暴露于这些药物的措施。 具体目标是：（1） 描述护士和药剂师在处理 药物和护士和助手在照顾 目前正在接受化疗的患者，（2）至 调查特定的工作实践是否与 对护士健康的急性、慢性或生殖影响， 药剂师和护士助手，（3）评估关系 工作实践和接触毒品之间的关系， 通过工业卫生试验和尿诱变剂试验测定， (4)调查内部和外部的关系 接触措施和临床实验室检测结果， 可能反映了暴露的影响。 所有受试者都将 护士和药剂师处理抗生素塑料和护士的助手 在参与成员处按治疗方案护理病人 NCI的NSABP项目的设施，包括私人 参与NSABP临床试验的医生办公室。 控制 将是未暴露的药剂师，护士，和助手，从这些相同的 设施 NSABP数据管理员将生成一个列表， 在他们的设施中暴露群体中的个人和 潜在的控制 数据将分两个阶段收集。 相 I是一项使用自我完成问卷的调查， 人口统计学和控制变量、暴露史和健康状况 和生殖史。 第二阶段将从子样本中收集 I期受试者，更新暴露和健康史，数据 其他可能影响尿液诱变的化学品暴露， 阿霉素暴露的工业卫生措施，血液和 用于临床实验室检查和尿致突变的尿样， 和曝光记录 一个基于工作实践的接触指数， 将从所有II期受试者中得出，并与数据进行比较 从工业卫生和尿液诱变剂测试和结果 从血液和尿液的临床实验室测试。

The objectives of this study are to determine whether handling antineoplastic drugs or caring for patients receiving treatment with these drugs presents a risk to the health of staff and to evaluate the relationship between work practices and various measures of exposure to these drugs. The specific aims are (1) to describe the work practices of nurses and pharmacists when handling antineoplastic drugs and of nurses and aides when caring for patients currently receiving antineoplastic treatment, (2) to investigate whether specific work practices are associated with acute, chronic, or reproductive effects on health among nurses, pharmacists and nurses' aides, (3) to evaluate the relationship between work practices and exposure to antineoplastic drugs as measured by an industrial hygiene test and a urine mutagen test and (4) to investigate relationships among internal and external exposure measures and results on clinical laboratory tests which may reflect effects of exposure. Subjects will be all exposed nurses and pharmacists who handle antineoplastics and nurses' aides caring for patients on treatment protocols at participating member facilities of the NSABP project of the NCI, including private physician's offices involved in NSABP clinical trials. Controls will be unexposed pharmacists, nurses, and aides from these same facilities. NSABP data managers will generate a list of individuals in the exposed groups at their facility and a list of potential controls. Data is to be gathered in two phases. Phase I is a survey using a self-completion questionnaire covering demographic and control variables, exposure history, and a health and reproductive history. Phase II will collect, from a subsample of subjects in Phase I, updated exposure and health histories, data on other chemical exposures which could affect urine mutagenesis, an industrial hygiene measure of adriamycin exposure, blood and urine samples for clinical laboratory tests and urine mutagenesis, and an exposure log. An exposure index, based on work practices, will be derived for all Phase II subjects and compared with data from the industrial hygiene and urine mutagen test and with results from the clinical laboratory tests on blood and urine.